NCT01975779View on ClinicalTrials.gov

Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

October 31, 2013

Conditions
Healthy
Interventions
DRUG

Cohort A1: Lu AE58054 or placebo

One single oral dose 60 mg (one 60 mg tablet) followed by 60 mg once daily for 7 days, or matching placebo.

DRUG

Cohort A2: Lu AE58054 or placebo

One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.

DRUG

Cohort B1: Lu AE58054

Two single oral doses 60 mg with \>=7 days washout.

Trial Locations (1)

NW10 7EW

GB001, London

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT01975779 - Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects | Biotech Hunter | Biotech Hunter